Cancer drug repurposed in bold bid to halt type 1 diabetes damage
NCT ID NCT06227221
Summary
This study is testing if sorafenib, a drug used for some cancers, can help preserve the body's own insulin production in adults recently diagnosed with type 1 diabetes. It will involve 10 participants who will take either the drug or a placebo for 26 weeks. The main goal is to see if the treatment can protect the pancreas cells that are under attack by the immune system in this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.